East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cephalexin Tablets USP, 250 mg and 500 mg. Aurobindo Pharma’s Cephalexin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Keflet Tablets manufactured by Eli Lilly and Company.

Cephalexin Tablets are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:

• Respiratory tract infections
• Otitis media
• Skin and skin structure infections
• Bone infections
• Genitourinary tract infections.